Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Six researchers from the Botnar Research Centre and the Kennedy Institute of Rheumatology at NDORMS have been awarded fellowships as part of the Oxford-Bristol Myers Squibb Fellowship Programme, providing them an opportunity to gain exposure to the field of commercial drug discovery and development.

Oxford-BMS fellows
From left to right: Stephanie Dakin, Udo Oppermann, Adam Cribbs, Christopher Buckley, Mark Coles, Elizabeth Mann

The Oxford-Bristol Myers Squibb Fellowship Programme was established in 2015 with the aim of stimulating new scientific discovery and translation and to generate a cohort of scientists that can navigate within and across both academic and industry spheres to bridge translational challenges.


Of the six new fellowships announced, three went to projects at NDORMS.

  • Stephanie Dakin and Christopher Buckley (Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences).
    Project: Frozen shoulder: A human disease model of resolving inflammatory fibrosis
  • Udo Oppermann and Adam Cribbs (Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences), with Karthik Ramasamy (Radcliffe Department of Medicine).
    Project: Exploring Polycomb repressive complex as therapeutic targets in high risk multiple myeloma patient subsets
  • Elizabeth Mann and Mark Coles (Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences), with Simon Leedham (Nuffield Department of Medicine).
    Project: Assessing and targeting adaptive epithelial-stromal-immune co-evolution solid tumours

'We are delighted to receive an Oxford-Bristol Myers Squibb Fellowship and look forward to establishing a fruitful and collaborative partnership. Our study aims to identify the distinct cell types and molecules responsible for driving inflammatory fibrosis in frozen shoulder, a common painful and debilitating musculoskeletal disease. This strong collaborative link between academia and pharma will help to reveal the cellular basis of inflammatory fibrosis. The Fellowship provides a unique opportunity to catalyse the development of new therapeutic strategies that selectively target or deplete pathogenic cell types, informing new therapies for patients with inflammatory fibrotic disease.'
- Stephanie Dakin, Principal Investigator for 2021 Oxford-Bristol Myers Squibb Fellowship

'It is a great pleasure to welcome Dr Charlotte Palmer as new BMS-Oxford fellow in our research groups at the Botnar Research Centre and the Oxford Centre for Translational Myeloma Research. Our research program with the BMS colleagues in the myeloma disease and therapeutics area continues with the aim to segment the complex genomic aberrations occurring in this haematological malignancy and use this information to specifically target underlying epigenetic mechanisms. Supported through this fellowship and by working with like-minded researchers in academia and industry allows us to focus on translational aspects and therapeutic utility of our research.'
- Udo Oppermann, Principal Investigator 2021 Oxford-Bristol Myers Squibb Fellowship.

'It is exciting to receive an Oxford-BMS fellowship with Prof. Simon Leedham to characterise and target cancer associated fibroblasts in colorectal and prostate cancer. Our work will analyse compare cancer fibroblast subsets between spontaneous mouse models and human tumours. This fellowship provides an opportunity to develop new approaches to treat check-point unresponsive tumours through targeting tumour stroma.'
- Mark Coles, Principal Investigator 2021 Oxford-Bristol Myers Squibb Fellowship.

As with all Oxford-Bristol Myers Squibb Fellows, the new Fellows will carry out world-leading research during their three-year postdoctoral research project and have a unique level of support available to them through the collaborations. Fellows also benefit from the direction and mentorship of Bristol Myers Squibb project leads and have opportunities to carry out research and use facilities at Bristol Myers Squibb labs in the US and Spain, in addition to accessing unique training opportunities.

Spearheaded by Professor Sir Marc Feldmann FRS of the Kennedy Institute at the University of Oxford and Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil., Executive Vice President, Research & Early Development, Bristol Myers Squibb, this active alliance between Bristol Myers Squibb and Oxford catalyses translational research and equips a cohort of researchers with an in-depth, real-world understanding of how research and development works within the biopharma industry. This has the long-term potential to lead to new discoveries that could benefit patients.

See the full story on the Medical Sciences website.

Similar stories

Fiona Powrie honoured by British Society for Immunology

Fiona Powrie was one of four researchers from the University of Oxford recognised for their outstanding contributions to immunology with Honorary Lifetime Membership of the British Society for Immunology.

The Kennedy Institute scoops sustainability award

A new roof extension was awarded the 2021 Green Award for Sustainability by the Oxford Preservation Trust alongside a Certificate in the New Building category.

Vaccination safety: generating accurate evidence is the clearest path to creating public trust

A new study shows that a vaccine surveillance method in observational data may generate high number of false positives

Fiona Powrie appointed new Deputy Chair of Wellcome’s Board of Governors

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.

A drug being trialled to treat cancer, could be the key to reducing gut inflammation

Published in Nature Communications, a new study reveals a new signalling pathway behind macrophage inflammatory activity

Single-cell ancestry vaccine research funded by the Chan Zuckerberg Initiative

The Chan Zuckerberg Initiative (CZI) has provided $2 million in funding to investigate how our ancestry and diversity influence the way that vaccines work in our cells.